The COVID-19 pandemic prompted a surge in antibody tests for SARS-CoV-2, leading to an evaluation of twelve laboratory and six point-of-care immunoassays across Canada.
There was significant variation in test performance, highlighting the need for an orthogonal testing strategy to enhance accuracy and consistency in results nationwide.
Manual tests had lower specificity and higher variability than automated tests, raising concerns about their effectiveness for large-scale monitoring, ultimately guiding public health decisions in Canada.